skip to the content

ACTEMRA: The First and Only Approved Treatment for Systemic Juvenile Idiopathic Arthritis (sJIA)

Tocilizumab is known as RoACTEMRA in the EU and Mexico and as ACTEMRA in other countries.

In April and August 2011, ACTEMRA/RoACTEMRA was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) respectively, for the treatment of active sJIA in patients 2 years of age and older, who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. ACTEMRA/RoACTEMRA can be given as monotherapy (in case of intolerance to methotrexate or where treatment with methotrexate is inappropriate) or in combination with methotrexate.

What is sJIA?

sJIA is a form of juvenile arthritis that begins in children under the age of 16 and has symptoms that affect the entire body in addition to the joints. Common systemic symptoms of sJIA may include fever, rash and muscle pain, but some patients may also experience further complications.

This section contains detailed scientific and medical information on sJIA, including further information about sJIA, and the role of IL-6 in sJIA.

Within this section there are several sJIA-specific ACTEMRA/RoACTEMRA resources available to download for healthcare professionals and patients, such as the healthcare professional brochure, patient brochure, sJIA dosing and administration guide, dosing poster, patient alert card and macrophage activation syndrome (MAS) summary card.

sJIA Resources

This section provides a wealth of useful information and practical items for both healthcare professionals and patients relating to the management of systemic juvenile idiopathic arthritis (sJIA) and the use of ACTEMRA/RoACTEMRA. More...